Phase
Condition
Diabetes And Hypertension
Diabetes Mellitus, Type 2
Diabetes Prevention
Treatment
Empagliflozin
Clinical Study ID
Ages 18-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.
Exclusion
Exclusion Criteria:
Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.
Study Design
Connect with a study center
Kabul University of Medical Sciences(KUMS)
Kabul 1138958, Afghanistan
AfghanistanCompleted
Kabul University of Medical Sciences(KUMS)
Kabul,
AfghanistanSite Not Available
Agha Khan univeristy hospital
Nairobi 184745, Kenya
KenyaActive - Recruiting
Agha Khan univeristy hospital
Nairobi,
KenyaSite Not Available
Lagos University Teaching Hospital
Lagos 2332459, Nigeria
NigeriaActive - Recruiting
Lagos University Teaching Hospital
Lagos,
NigeriaSite Not Available
Umar Diabetes Foundation
Islamabad,
PakistanSite Not Available
Umar Diabetes Foundation
Islamabad 1176615,
PakistanCompleted
National hospital Sri Lanka
Colombo 1248991, Colombo
Sri LankaCompleted
NHK
Kandy 1241622, Kandy
Sri LankaCompleted
NHSL
Colombo,
Sri LankaSite Not Available
National hospital Sri Lanka
Colombo,
Sri LankaSite Not Available
NHK
Kandy,
Sri LankaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.